integrations of Epichem and Molecular Medicine BioServices, both
acquired during the first half of 2007, into our SAFC unit continue on
schedule, adding $52 million in annualized revenue growth from
acquisitions in desirable technology platforms and businesses. As
always, we continue to evaluate and hold discussions with additional
acquisition candidates on an ongoing basis, some of which may well add
to our future revenue base."
Nagarkatti concluded, "We expect our positive momentum to carry into and throughout 2008, enabling us to meet our 7% organic sales growth goal, generate further margin expansion and deliver strong EPS growth. I'm confident about our ability to deliver both our targeted sales growth and our EPS forecast of $2.52 to $2.62 for the year."
SALES RESULTS (all percentage comparisons are to comparable periods in 2006):
A reconciliation of reported and adjusted sales growth and quarterly sales by business unit can be found in tabular form in the Supplemental Financial Information section on page 10.
Reported sales increased 14.6% and 13.4% for the fourth quarter and full year 2007, respectively. Fourth quarter and full year organic sales growth, excluding currency benefits and a contribution from the February 2007 acquisition of Epichem, were 5.5% and 6.5%, respectively. Highlights for our four business units included:
Research Specialties (Reported growth: Q4: 15.5%, 2007: 13.6%; Organic
growth: Q4: 7.7%, 2007: 8.3%): This unit continued its exceptional
performance in Q4 2007 by exceeding its 6% long-term organic growth target
for the sixth consecutive quarter. Demand remained strong in all customer
segments, product initiatives and geographies, with particularly strong
growth in the industrial and services/testing segments in the U.S. and the
analytical, chemical, biochemistry and lab equipment produc
|SOURCE Sigma-Aldrich Corporation|
Copyright©2008 PR Newswire.
All rights reserved